Portal de investigação
Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Martins, RS
- Jesus, TT
- Cardoso, L
- Vinagre, J
Unidades de investigação
Abstract
Medullary thyroid carcinoma (MTC) arises from parafollicular cells in the thyroid gland, and although rare, it represents an aggressive type of thyroid cancer. MTC is recognized for its low mutational burden, with point mutations in RET or RAS genes being the most common oncogenic events. MTC can be resistant to cytotoxic chemotherapy, and multitarget kinase inhibitors (MKIs) have been considered a treatment option. They act by inhibiting the activities of specific tyrosine kinase receptors involved in tumor growth and angiogenesis. Several tyrosine kinase inhibitors are approved in the treatment of advanced MTC, including vandetanib and cabozantinib. However, due to the significant number of adverse events, debatable efficiency and resistance, there is a need for novel RET-specific TKIs. Newer RET-specific TKIs are expected to overcome previous limitations and improve patient outcomes. Herein, we aim to review MTC signaling pathways, the most recent options for treatment and the applications for personalized medicine.
Dados da publicação
- ISSN/ISSNe:
- 2075-4426, 2075-4426
- Tipo:
- Review
- Páginas:
- 1132-
- DOI:
- 10.3390/jpm13071132
- Link para outro recurso:
- www.scopus.com
Journal of Personalized Medicine Multidisciplinary Digital Publishing Institute (MDPI)
Citações Recebidas na Scopus: 5
Documentos
- Não há documentos
Filiações
Keywords
- MTC; RET; signaling pathways; TKIs; multikinase inhibitors; RET-specific inhibitors
Campos de estudo
Financiamento
Proyectos asociados
Selenium Clinical Supplementation In Autoimmune Thyroid Disease: A Portuguese Survey
Investigador Principal: Ana Paula Soares Dias Ferreira
Estudo Clínico Académico . 2022
Squamous cell carcinogenesis of the skin: Molecular characterization of prognostic therapeutic biomakers
Investigador Principal: Ana Paula Soares Dias Ferreira
Estudo Clínico Académico . 2022
Clinicopathological features and molecular biomarkers? role predicting papillary thyroid cancer patients? outcome: How to personalize and guide surgical treatment
Investigador Principal: Ana Paula Soares Dias Ferreira
Estudo Clínico Académico . 2022
Fatores do microambiente tumoral no cancro do ovário.
Investigador Principal: Ana Paula Soares Dias Ferreira
Estudo Clínico Académico . 2022
Citar a publicação
Martins RS,Jesus TT,Cardoso L,Soares Dias Ferreira A,Vinagre J. Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments. J. Pers. Med. 2023. 13(7):p. 1132-1132. IF:3,508. (2).
